Brolucizumab
未知生产厂商
Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF, VEGF, and VEGF. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
